WO2016111276A1 - Sphingolipid absorption promoter - Google Patents

Abstract

A sphingolipid absorption promoter that comprises as an active ingredient a fermentation product and/or a culture product of a lactic acid bacterium and/or a bifidobacterium. According to the present invention, when a sphingolipid is taken, the absorption of the sphingolipid can be improved or promoted and thus the sphingolipid can be safely easily and economically (or efficiently) absorbed.

Description

Sphingolipid absorption promoter Reference to related applications

This application is based on Japanese Patent Application No. 2015-000745 (filing date: January 6, 2015), which is a prior Japanese patent application, and claims the benefit of its priority. The entirety is hereby incorporated by reference.

The present invention relates to a sphingolipid absorption promoter (Absorption Promoter of Sphingolipid). The present invention also relates to a composition for oral ingestion or enteral administration comprising a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria and an additional sphingolipid.

Sphingolipid is a component that constitutes eukaryotic cell membranes, and is a generic name for lipids having sphingoid bases. It has been clarified that the effect of improving the barrier function of the skin based on oral ingestion.

Sphingomyelin is one of milk-derived sphingolipids. For sphingomyelin, preventive and improving effects on skin conditions (decrease in skin barrier function, dryness and roughness of skin, decrease in water content of stratum corneum, atopic dermatitis, etc.) based on ingestion Etc. have been revealed.

Furthermore, about sphingomyelin, cancer (colon cancer) inhibitory action (Tatsuya Sugawara, “Digestion and absorption of sphingolipid as a functional food ingredient”, Journal of Japanese Society of Nutrition and Food, Vol. 66, No. 4, pp.177 -183 (2013)), skin beautification (Japanese Patent Laid-Open No. 2008-184428), infant brain development promoting action (Patent No. 3203485), mitochondrial function improving action (Japanese Patent Laid-Open No. 2011-157329), motor function improving action ( JP-A-2014-14196), visceral fat accumulation suppression and blood adiponectin concentration increase promoting action (anti-hyperglycemic action, anti-hyperlipidemic action) (JP-A 2007-320900), infectious disease preventing action (special No. 2008-037788) is known.

Sphingomyelin is a substance composed of ceramide and phosphocholine and is hydrolyzed to ceramide and phosphocholine by sphingomyelinase. Furthermore, ceramide is hydrolyzed by ceramidase into sphingoid bases and fatty acids, many of which are absorbed as fatty acids by epithelial cells of the small intestine, and some sphingoid bases are converted into sphingomyelin, ceramide, etc. Recombined. It has been suggested that sphingomyelin is degraded by enteric bacteria.

Glucosylceramide is a substance in which glucose is bound to ceramide composed of sphingo base and fatty acid. It is hydrolyzed to ceramide and glucose by glucoceramide-degrading enzyme. Galactosylceramide is a substance in which galactose is bound to ceramide composed of a sphingo base and a fatty acid.

Generally, when lipids are taken orally, they are emulsified by bile acids, decomposed into fatty acids and monoglycerides by lipase, and absorbed in the small intestine. Furthermore, monoglycerides are re-synthesized into triacylglycerol in the epithelial cells of the small intestine, converted into chylomicrons, sent to the lymphatic vessels, pass through the thoracic duct, and then enter the systemic circulation.

However, it has been clarified that sphingomyelin and ceramide have low digestibility and absorption. Possible causes include the low activity of sphingomyelinase in the gastrointestinal tract and the elimination of sphingoid bases once absorbed by the transporter expressed there.

Therefore, when a sphingolipid containing sphingomyelin, which is expected to have various effects as described above, is orally ingested, it is possible to increase the absorbability of the sphingolipid, and there is a safe, simple and efficient ingestion means. It was desired.

Regarding improving the digestion and absorption of lipids, for example, Patent No. 3920969 proposes a nutritional composition containing bile acids and bile salts in order to improve the digestion and absorption of lipids. However, it does not describe sphingolipids here, and bile acids themselves are bitter, and their effects must be taken into account when used as food.

Fermented milk (yogurt) is a fermented food prepared by mixing lactic acid bacteria and yeast in milk and fermenting it, and is widely eaten from the viewpoint of its deliciousness, beauty and health.

For example, Japanese Patent Application Laid-Open No. 7-327633 discloses a chitosan processed food in which chitosan, wheat and wheat yogurt are mixed. Here, it is described that powdered yogurt has a function of assisting in digestion and absorption of chitosan. However, the digestive absorption function here focuses on the action of active lecithin in powdered yogurt, and there is no disclosure or suggestion about the promotion of digestive absorption of sphingolipids.

The present inventors have unexpectedly found that when fermented milk (yogurt) is ingested simultaneously with sphingomyelin, the amount of sphingomyelin absorbed can be increased, that is, the absorption of sphingomyelin is improved unexpectedly. I also found. At this time, the present inventors have also found that absorption of ceramide is improved. From these facts, the present inventors have found that absorption of sphingolipids can be promoted by ingestion of fermentation products and / or cultures of lactic acid bacteria and / or bifidobacteria. Furthermore, by improving the amount of sphingolipids, including sphingomyelin, absorbed in the body, the skin barrier function expected with the absorption of sphingolipids is improved, and various beneficial effects and effects are improved. Can be planned. And the present inventors actually improved the amount of sphingomyelin absorbed into the living body by preparing an oral or enteral composition containing yogurt and sphingomyelin exceeding the yogurt content. confirmed. The present invention is based on these findings.

Therefore, the present invention is a means capable of improving or promoting the absorption of sphingolipids when ingesting sphingolipids, which is safe, simple and economical (or efficient). The purpose is to provide.

That is, according to the present invention, the following inventions are provided.

<1> A sphingolipid absorption promoter comprising as an active ingredient a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria.

<2> In the sphingolipid absorption promoter according to <1>, the sphingolipid is sphingomyelin, and it is preferable to promote absorption of the sphingomyelin into the living body.

<3> In the sphingolipid absorption promoter of <2>, it is preferable to promote absorption of milk-derived sphingomyelin into the living body.

<4> In the sphingolipid absorption promoter according to any one of <1> to <3>, the sphingolipid may be any one or more of ceramide, glucosylceramide, and galactosylceramide.

<5> In the sphingolipid absorption promoter according to any one of <1> to <4>, the fermented product and / or culture product of lactic acid bacteria and / or bifidobacteria is a milk fermented product of lactic acid bacteria and / or bifidobacteria and / or Or it may be a milk culture.

<6> A sphingolipid absorption promoter comprising a polysaccharide as an active ingredient.

<7> A composition for oral ingestion or enteral administration, comprising the sphingolipid absorption promoter according to any one of <1> to <6> above and a sphingolipid.

<8> A composition for oral ingestion or enteral administration, comprising a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria and an additional sphingolipid.

<9> The composition for oral ingestion or enteral administration according to <7> or <8> above, wherein the blending ratio of the lactic acid bacteria and / or bifidobacteria fermented product and / or culture product to the sphingolipid is a sphingolipid. 1 mg of lactic acid bacteria and / or bifidobacteria fermented and / or cultured (dry weight (powder)) may be included at 1 to 10,000 mg.

<10> In the composition for oral ingestion or enteral administration described in <7> or <8> above, the blending ratio of the lactic acid bacteria and / or bifidobacteria fermented product and / or culture product to the sphingolipid is determined as a sphingolipid. 1 mg of lactic acid bacteria and / or bifidobacteria fermented and / or cultured (wet weight) may be included in an amount of 0.01 to 100 g.

<11> In the composition for oral ingestion or enteral administration according to any one of <7> to <10>, the sphingolipid may be sphingomyelin.

<12> The composition for oral intake or enteral administration according to any one of the above <7> to <11> is used for an in vivo action induced by absorption of sphingomyelin into the living body. Good.

<13> In the composition for ingestion or enteral administration according to <12> above, the in vivo action of <7> is prevention or improvement of skin condition deterioration, cancer suppression action, skin beautification, infant brain It is preferable to be selected from the group consisting of a development promoting action, a mitochondrial function improving action, a motor function improving action, a visceral fat accumulation suppressing action and a blood adiponectin concentration raising promoting action, and an infectious disease preventing action.

<14> The composition for oral intake or enteral administration according to any one of the above <7> to <11> may be used for prevention, suppression or improvement of skin condition deterioration.

<15> In the composition according to <14>, the deterioration of the skin state may be a deterioration of the skin barrier function.

<16> A food or drink comprising the sphingolipid absorption promoter of any one of <1> to <6> or the composition of any one of <7> to <15>.

<17> The food and drink according to <16> may be a functional food, a health nutrition food, a supplement, a food for specified health use, a functional display food, or a food with a disease risk reduction display.

<18> Fermented and / or cultured lactic acid bacteria and / or bifidobacteria simultaneously with sphingolipids, or ingested or enterally administered to a subject in whom sphingolipids are desired. Absorption promotion method.

<19> In the absorption promotion method according to <18>, the sphingolipid may be sphingomyelin.

According to the sphingolipid absorption enhancer of the present invention, when sphingomyelin is ingested, the absorption of sphingomyelin can be improved or promoted, and further, safe, simple and economical (or efficient) sphingomyelin. Can be absorbed. The yogurt used in the absorption enhancer and composition of the present invention has experience in use as a conventional food, so it is highly safe, simple in actual consumption, and economically advantageous. is there.

It is a graph which shows the result (change (integrated value)) of the result of Example 1 (ceramide molecular species amount in lymph fluid). It is a graph which shows the result (change (integrated value)) of the amount of sphingomyelin molecular species amount in a lymph fluid of Example 1. It is a graph which shows the result (change of the ceramide molecular species amount in serum) of Example 2 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group). It is a graph which shows the result (area under the time curve of the ceramide molecular species amount in serum) of Example 2 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group. ). It is the graph which showed transition of the stratum corneum moisture content in Test 1 of Example 3 (there is a significant difference (p <0.05) between different alphanumeric characters). It is the graph which showed transition of the transdermal water transpiration amount in Test 1 of Example 3 (there is a significant difference (p <0.05) between different alphanumeric characters). FIG. 5 is a graph showing the results of Example 4 (area under the time curve of the amount of ceramide molecular species in serum) (in the figure, * means that there is a significant difference (P <0.05) from the MPL group). , # Means that there is a significant difference (P <0.05) with respect to the unfermented milk group). It is a graph which shows the result (area under the time curve of the ceramide molecular species amount in serum) of Example 5 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group. ). It is a graph which shows the result (area under the time curve of the ceramide molecular species amount in serum) of Example 6 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group). ). It is a graph which shows the result (the area under the time curve of the ceramide molecular species amount in serum) of Example 7 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group. ). It is a graph which shows the result (the area under the time curve of the ceramide molecular species amount in serum) of Example 8 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group. ). It is a graph which shows the result (area under the time curve of the ceramide molecular species amount in serum) of Example 9 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group. ). It is a graph which shows the result (area under the time curve of the ceramide molecular species amount in serum) of Example 10 (in the figure, * means that there is a significant difference (P <0.05) with respect to the MPL group). ).

Hereinafter, embodiments of the present invention will be described.

Sphingolipid absorption enhancer As described above, the sphingolipid absorption enhancer of the present invention contains a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria as an active ingredient. Here, the term “active ingredient” means that the absorption promoter according to the present invention is used in a sufficient amount (ie, effective amount) of lactic acid bacteria and / or sufficient to exert the action of promoting the absorption of sphingolipids in vivo. It means containing a fermented product and / or culture product of bifidobacteria.

In addition, here, “absorption promotion” of sphingolipid means promoting absorption of the sphingolipid into the living body. The term “absorption” as used herein typically refers to a sphingolipid that has been orally or enterally administered simultaneously or sequentially with the absorption enhancer of the present invention, or a sphingolipid that has already been ingested into the body. It is taken up into the circulatory organs (vascular system and lymphatic system) in the living body through the biological membrane in the digestive tract and the absorption tract, etc., so that the actually absorbed sphingolipid is sphingolipid or its induction. As a substance, it is possible to exert various actions on the living body.

The term “promotion” as used herein means that the absorption of sphingolipids is promoted compared to the case where no absorption enhancer is used. Here, the amount of absorption increases and the rate of absorption is increased. Includes improving, improving reduced absorption and the like. In the preferred embodiment of the present invention, “promotion” is used in the sense of increasing the amount of sphingolipid absorbed into the living body.

In the present specification, sphingolipids are naturally derived, such as those derived from milk such as cow's milk, goat milk, sheep milk, and horse milk, those derived from egg yolk, those derived from soybeans, rice, corn, and grains. , Derived from konjac, beet-derived and the like, preferably derived from milk, more preferably derived from milk. Sphingolipids include sphingomyelin, glucosylceramide, and galactosylceramide. The sphingolipid is preferably a sphingophospholipid, more preferably a sphingomyelin. These can be prepared from natural raw materials by a conventional method, but commercially available products may be used.

In the present invention, the sphingomyelin that can be used is one of sphingolipids and, like the sphingolipids described above, is naturally derived, preferably milk-derived, more preferably milk-derived. belongs to. Sphingomyelin can be prepared from natural raw materials by a conventional method, but a commercially available product may be used.

According to a preferred embodiment of the present invention, absorption of milk-derived sphingomyelin into the living body is promoted in the sphingolipid absorption promoter.

In the present invention, the absorption of sphingolipid (for example, sphingomyelin) can be evaluated by measuring the amount of sphingolipid into the living body. At this time, for example, the absorption of sphingomyelin may be evaluated by paying attention to a certain molecular species of sphingomyelin and measuring the amount of the molecular species taken into the living body. Alternatively, the absorption of sphingomyelin can be evaluated by measuring the amount of a sphingomyelin inducer, for example, ceramide produced by hydrolysis of sphingomyelin, taken into the living body.

In general, examples of molecular species contained in sphingomyelin, particularly milk-derived sphingomyelin, include the following:
That is, it is a sphingomyelin molecular species in which phosphocholine or phosphoethanolamine is bound to a ceramide structure in which sphingosine or dihydrosphingosine having a carbon chain number of 16 to 18 and a fatty acid having a carbon chain of 14 to 26 are amide-bonded respectively.

The absorption of sphingomyelin can be evaluated by focusing on one or a combination of a plurality of these molecular species and measuring the amount or the amount of the inducer.

As described above, sphingomyelin is a substance composed of ceramide and phosphocholine, and is hydrolyzed into ceramide and phosphocholine by sphingomyelinase. Ceramide is further hydrolyzed to sphingoid base and fatty acid by ceramidase. For this reason, the sphingolipid absorption promoter promotes the absorption of sphingomyelin and also promotes the absorption of ceramide into the living body.
For this reason, according to the sphingolipid absorption enhancer of the present invention, absorption of ceramide into the living body is also promoted.

According to another aspect of the present invention, there is also provided an absorption promoter for ceramide, glucosylceramide, and / or galactosylsalamide containing a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria as an active ingredient. According to such a ceramide, glucosylceramide, and / or galactosylsalamide lipid absorption enhancer according to the present invention, absorption of ceramide, glucosylceramide, galactosylsalamide, or a combination of two or more thereof into a living body is also promoted. The

In the present invention, examples of the molecular species contained in ceramide, glucosylceramide, and galactosylceramide include the following:
That is, ceramide molecular species in which sphingosine, dihydrosphingosine, sphingadienin, phytosphingosine or hydroxysphingenin having 16 to 18 carbon chains and amide bonds of fatty acids or hydroxy fatty acids having 14 to 26 carbon chains, respectively. Glucosylceramide molecular species in which glucose is bound to the above ceramide molecular species. This is a galactosylceramide molecular species in which galactose is bound to the above ceramide molecular species.

In the present invention, the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” means a fermented product of lactic acid bacteria and bifidobacteria, a fermented product of lactic acid bacteria, a fermented product of bifidobacteria, a cultured product of lactic acid bacteria and bifidobacteria, Used to include lactic acid bacteria cultures, bifidobacteria cultures, and combinations thereof.

In the present invention, the term “lactic acid bacteria” is a general term for microorganisms that assimilate glucose and produce lactic acid with a yield of sugar of 50% or more. It has characteristics such as lack of spore formation and negative catalase. Lactic acid bacteria have been eaten from around the world through fermented milk since ancient times, and can be said to be extremely safe microorganisms. To date, lactic acid bacteria have been classified into 11 genera of Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, Streptococcus, Wissella, Tetragenococcus, Oenococcus, Enterococcus, Vagococcus, and Carnobacterium. In the present invention, these lactic acid bacteria can be used. Among these, preferable Lactobacillus includes, for example, Lactobacillus genus, that is, Lactobacillus eckdelbrueckii subsp. Bulgaricus, Streptococcus thermophilus, Lactobacillus lactis, Lactobacillus gasseri and the like. In particular, it is preferable to use a mixed starter of Lactobacillus delbrueckii subsp. Bulgaricus and Streptococcus thermophilus.

In the present invention, “Bifidobacterium” is a microorganism that assimilates glucose to produce acetic acid and lactic acid, and belongs to the genus Bifidobacterium. Examples include Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium breve and the like.

According to one preferred embodiment of the present invention, the lactic acid bacteria include a combination of Bulgarian bacteria and thermophilus bacteria, and more preferably a combination of Bulgarian bacteria and thermophilus bacteria.

In the present invention, the “fermented product” refers to a culture itself obtained by fermentation with lactic acid bacteria and / or bifidobacteria. In the present invention, “fermented product” refers to a fermented product of lactic acid bacteria and / or bifidobacteria and a processed product thereof, for example, the culture (lactic acid bacteria and / or bifidobacteria fermented product) removed by filtration, centrifugation, membrane separation, or the like. Concentrated, pasted, diluted or (frozen, concentrated or concentrated, etc.) the culture filtrate or culture supernatant obtained by fungi, the culture filtrate / culture supernatant, lactic acid bacteria and / or bifidobacteria fermentation product, etc. Heat, reduced pressure, etc.) include dried products.
Furthermore, in the present invention, when creating a processed product, one or more of the above-described processing steps such as sterilization treatment such as filtration, centrifugation, and membrane separation, precipitation, concentration, pasting, dilution, and drying are combined. Can be used.

In the present invention, examples of the culture medium include nonfat dry milk medium and MRS medium supplemented with yeast extract.

According to one preferred embodiment of the present invention, the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” is a fermented milk and / or milk culture of lactic acid bacteria and / or bifidobacteria. Furthermore, according to one more preferable aspect of the present invention, the “fermented product and / or culture product of lactic acid bacteria and / or bifidobacteria” is fermented milk (yogurt). Here, the yogurt may be a supernatant thereof. According to one more preferred embodiment of the present invention, the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” is a polysaccharide. Here, the polysaccharide is preferably derived from a fermentation product and / or a culture product.

Therefore, according to another aspect of the present invention, a sphingolipid absorption promoter comprising a polysaccharide as an active ingredient is provided.

In the present invention, “milk fermented product and / or milk culture”, that is, “milk fermented product and / or milk cultured product” refers to a product obtained by fermenting or culturing a raw material containing milk. Examples of milk include animal milk such as cow milk and processed products thereof (eg, skim milk, whole milk powder, skim milk powder, spinach, casein, whey, fresh cream, compound cream, butter, buttermilk powder, etc.) And vegetable milk such as soybean milk derived from soybean.

As a raw material of fermented milk, what is called fermented milk raw material mix is mentioned, for example.
The fermented milk raw material mix is a mixture containing raw milk and other ingredients, such as raw milk, water, and other optional ingredients (for example, sugar, sugar, sweetener, acidulant, mineral, vitamin, flavor, etc.) It can obtain by heating, melt | dissolving, and mixing the raw material normally used for manufacture of fermented milk. Fermented milk can use thickeners and gelling agents such as pectin, guar gum, xanthan gum, carrageenan, and processed starch in culture solutions such as skim milk powder and whey degradation products. Milk includes those before sterilization and those after sterilization. Specific ingredients (materials) of raw milk include water, raw milk, pasteurized milk, skim milk, whole milk powder, skim milk powder, whole fat concentrated milk, skim concentrated milk, butter milk, butter, cream, etc. Also good. Further, whey protein concentrate (WPC), whey protein isolate (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg) and the like may be included.

The method for producing fermented milk includes a raw material mix preparation step in which raw materials are mixed (prepared). What is necessary is just to employ | adopt suitably the normal conditions used when manufacturing fermented milk in the preparation process of a raw material mix. Furthermore, the method for producing fermented milk of the present invention includes a raw material mix (heating) sterilization step, a raw material mix cooling step, a starter addition step, a fermentation step, and a fermented milk cooling step, as in the conventional method. It is desirable to include in this order. In addition, what is necessary is just to employ | adopt suitably the normal conditions used when manufacturing fermented milk in these processes.

As a medium for culturing lactic acid bacteria and the like, a medium usually used can be used. That is, any medium can be used as long as it contains a nitrogen source, inorganic substances and other nutrients in addition to the main carbon source. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolyzate, waste molasses and the like can be used according to the assimilation ability of the bacteria used. As the nitrogen source, organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, α-lactalbumin, β-lactoglobulin, glycomacropeptide, and soy protein hydrolyzate can be used. In addition, as the growth promoter, meat extract, fish extract, yeast extract and the like can be used.

As conditions for culturing lactic acid bacteria and the like, an anaerobic state is preferable, but a microaerobic state by liquid stationary culture ordinarily used may be used. For this anaerobic culture, a known method such as a method of culturing in a carbon gas gas layer can be applied, but other methods may be used. In general, the culture temperature is preferably 30 to 47 ° C, more preferably 35 to 46 ° C, and still more preferably 37 ° C to 45 ° C. The pH of the medium in which lactic acid bacteria and the like are cultured is preferably maintained at 6 to 7, but other pH conditions may be used as long as the temperature allows the bacteria to grow. The culture time for lactic acid bacteria and the like is usually preferably 1 to 48 hours, more preferably 8 to 36 hours, still more preferably 10 to 24 hours.

As a typical example of fermented milk (yogurt) in the present invention, the solid content of non-fat milk is 8% by weight or more, and the number of lactic acid bacteria or the number of yeasts is 10 million / ml or more. For example, it is 10 ¹¹ pieces / ml or less.

Use The fermented product and / or culture of lactic acid bacteria and / or bifidobacteria, which are active ingredients of the present invention, have sphingolipid absorption promoting activity (Examples 1 and 2 to be described later), and usually ceramide absorption promoting activity. Also have. Therefore, the use of the sphingolipid absorption promoter of the present invention can improve the absorption of the sphingolipid in the living body, and thus various effects exhibited by the presence of the sphingolipid or its derivative in the living body. Can be further improved. This point is naturally the same when the sphingolipid is sphingomyelin, and by using the sphingomyelin absorption promoter of the present invention, it is possible to improve the absorption of sphingomyelin in vivo, Various actions exhibited by the presence of sphingomyelin or a derivative thereof in a living body can be further improved.

Furthermore, similarly, when the sphingolipid is ceramide, glycosyl ceramide, or galactosyl ceramide, by using the ceramide, glycosyl ceramide, or galactosyl ceramide absorption enhancer of the present invention, in vivo ceramide, glycosyl ceramide, or Absorption of galactosylceramide can be improved. For this reason, various actions exhibited by the presence of ceramide, glycosylceramide, or galactosylceramide and their derivatives in vivo can be further improved.

Deterioration of skin condition due to increased presence of sphingomyelin or its inducer in the body (decreased skin barrier function, dry skin and skin, decreased moisture content of stratum corneum, atopic dermatitis, etc. ) Can be improved, improved, enhanced, and improved in preventive effect.

In addition, by increasing the amount of sphingomyelin or its inducer in vivo, cancer (colon cancer) inhibitory action (Tatsuya Sugawara, “Digestion and absorption of sphingolipid as a food functional ingredient”, Japanese nutrition and food Academic Journal, Vol. 66, No. 4, pp. 177-183 (2013)), skin beautification (JP 2008-184428), infant brain development promotion (Patent No. 3203485), mitochondrial function improvement (JP 2011-157329), motor function improving action (Japanese Patent Laid-Open No. 2014-14196), visceral fat accumulation suppression and blood adiponectin concentration increase promoting action (anti-hyperglycemic action, anti-hyperlipidemic action) (JP 2007) -320900), infectious disease prevention action (Japanese Patent Laid-Open No. 2008-037788), and the like.

Therefore, these effects can be obtained by promoting the absorption of sphingolipids by the sphingolipid absorption promoter of the present invention.

Furthermore, as shown in Example 3 to be described later, by promoting the absorption of sphingolipid, the skin barrier function can be further improved in the state where the skin barrier function is lowered by ultraviolet rays.

In the present invention, the deterioration of the skin condition includes, for example, a reduction in skin barrier function, skin drying, skin roughness, a decrease in the amount of water in the stratum corneum, and atopic dermatitis. Reduction of the barrier function of the skin includes maintenance of the barrier function. Further, the reduction in the skin barrier function is preferably a reduction in the skin barrier function under the irradiation of ultraviolet rays.

Also, here, “prevention, suppression or improvement” of an exacerbated state is used in a sense encompassing adjustment, delay of progression, mitigation, prevention of onset, prevention of recurrence, etc. of such a state.

Therefore, according to the present invention, it is possible to increase the amount of sphingolipid absorbed in the living body by promoting the absorption of the sphingolipid, and as a result, the in vivo action (function) induced by the absorption of the sphingolipid into the living body. , Efficacy) can be improved, improved and enhanced. The in vivo action referred to here is induced by absorption of sphingolipid into the living body, and specifically has various effects as described above. Therefore, according to the present invention, it is also possible to provide an enhancer of an action (function) in vivo induced by absorption of sphingolipid (an enhancer of function accompanying absorption (ingestion) of sphingolipid).

Composition for Oral Intake or Enteral Administration As described above, according to the present invention, the active ingredient of the present invention, that is, a fermented and / or cultured product of lactic acid bacteria and / or bifidobacteria, and a sphingolipid. A composition for oral ingestion or enteral administration is provided. It can also be said that this composition comprises the sphingolipid absorption promoter of the present invention as such an active ingredient.

Lactic acid bacteria and / or bifidobacteria fermentations and / or cultures often already contain sphingolipids themselves, but in a preferred embodiment of the invention the composition of the invention comprises lactic acid bacteria and And / or bifidobacteria fermentation and / or culture and additional sphingolipids. For this reason, the composition of the present invention can be distinguished from a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria such as conventional yogurt.
Here, “additional sphingolipid” refers to a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria when a sphingolipid is contained in the fermented product and / or culture of lactic acid bacteria and / or bifidobacteria. It means a sphingolipid that is additionally present in the composition beyond the amount of the sphingolipid itself contained in the product.

As the additional sphingolipid, the sphingolipid itself may be used as it is, and examples thereof include a high content phospholipid concentrate (MPL) of milk-derived sphingomyelin. It can also be obtained as an insoluble fraction of acetone (solvent) and / or ethanol from cream or butter or from butter ram which is a by-product in producing butter oil. Bataselam is also used in the city milk field and is available (for example, manufactured by Tatua, New Zealand). Bataselam is rich in MFGM in which sphingomyelin is localized, and is suitable as a raw material.

In order to separate the fraction of phospholipids where sphingomyelin is localized from Bataselam, the property that phospholipids are insoluble in acetone and / or ethanol is used. Acetone-soluble fraction containing neutral lipid is removed by multiple extractions of acetone to obtain an acetone-insoluble fraction enriched in phospholipid. The acetone-insoluble fraction is concentrated under reduced pressure to remove acetone, and the concentrate is freeze-dried after sterilization, and then the dried product is crushed to obtain a milk-derived phospholipid fraction. May be used against.

In addition, the total lipid was extracted from chicken skin powder, and the dried total lipid was dried and extracted with a mixed solvent of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent, and an insoluble portion mainly composed of sphingomyelin was removed. And a method for extracting sphingomyelin by extraction with a mixed solvent of water and a water-soluble ketone solvent and removing non-lipid components contained in the soluble part. Existing methods such as extraction methods from seafood and animal birds can be used. From the viewpoint of flavor, milk-derived sphingomyelin is preferred.

In the composition of the present invention, fermented products and / or cultures of lactic acid bacteria and / or bifidobacteria are set type yogurt (solid fermented milk), soft type yogurt (pasted fermented milk), drink yogurt (liquid fermented milk). Various forms of yogurt such as cereals, fruits, vegetables, and nutrient ingredients may also be used.

The composition for oral ingestion or enteral administration of the present invention is preferably one in which the absorption of sphingolipids into the living body is enhanced, more preferably the absorption of sphingomyelin into the living body is enhanced. It is a thing. That is, the composition for oral ingestion or enteral administration of the present invention can be referred to as a “sphingolipid superabsorbent”, preferably a “sphingomyelin superabsorbent” composition for oral ingestion or enteral administration. Note that “high sphingolipid absorbency” or “high sphingomyelin high absorbency” is to be compared with the amount of sphingomyelin absorbed in the case of an existing yogurt or the like as in Example 1 or 2 described later, for example. Can be confirmed.

From the viewpoint of superabsorbency of sphingolipid or superabsorbency of sphingomyelin, in the composition for oral intake or enteral administration of the present invention, a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria, and sphingo The blending ratio with lipid is preferably 1 to 10000 mg, more preferably 5 to 5000 mg of lactic acid bacteria and / or bifidobacteria fermentation and / or culture (dry weight (powder)) per 1 mg of sphingolipid. More preferably, it is contained in an amount of 10 to 750 mg.

Similarly, from the viewpoint of the high absorbability of sphingolipid or the high absorbability of sphingomyelin, the fermented product and / or culture of lactic acid bacteria and / or bifidobacteria in the composition for oral consumption or enteral administration of the present invention And the ratio of sphingolipid to 1 mg of sphingolipid, preferably 0.01 to 100 g, more preferably 0.05 to lactic acid bacteria and / or bifidobacteria fermented product and / or culture (wet weight). To 50 g, more preferably 0.1 to 7.5 g.

The composition for oral ingestion or enteral administration of the present invention is preferably used for in vivo action induced by absorption of sphingomyelin into the living body. The composition for oral ingestion or enteral administration according to the present invention is more preferably such that the action in the living body is prevention or improvement of skin condition deterioration, cancer suppression action, skin beautification, infant brain development promotion. It is used for an action selected from the group consisting of an action, an action to improve mitochondrial function, an action to improve motor function, an action to suppress visceral fat accumulation and an increase in blood adiponectin concentration, and an action to prevent infection.

The composition for oral intake or enteral administration of the present invention is preferably used for preventing, suppressing or improving the deterioration of the skin condition. Here, the deterioration of the skin condition is preferably a deterioration of the barrier function of the skin. And it is preferable that the deterioration of the barrier function of the skin is due to the irradiation of ultraviolet rays.

The composition of this invention can be a pharmaceutical composition as one preferable aspect.
In the present invention, the pharmaceutical composition is prepared as an oral preparation or a parenteral preparation according to a conventional method using additives that are acceptable for formulation. From the viewpoint of simplicity, an oral preparation is preferable. For oral preparations, take the form of solid preparations such as tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, and liquid preparations such as solutions, suspensions, and emulsions. Can do. Additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, fragrances, buffers, antioxidants, pH Examples thereof include regulators.

Also, according to the present invention, there is provided a food or drink comprising the sphingolipid absorption promoter of the present invention or the composition for oral intake or enteral administration described above.

Such a composition and food / beverage products of this invention are manufactured by the manufacturing method which comprises adding the absorption promoter of this invention, or its active ingredient to the composition and the material component of food / beverage products, for example. Can do.

Arbitrary ingredients can be added to the food and drink of the present invention as required. As such optional components that can be added, there are no particular restrictions, but usually ingredients to be blended in foods and drinks, sweeteners, acidulants, vegetable and fruit juices and their extracts, vitamins, minerals, Nutrients such as amino acids, useful microorganisms such as lactic acid bacteria, bifidobacteria and propionic acid bacteria and their cultures, functional sugars such as oligosaccharides, royal jelly, collagen, ceramide, glucosamine, astaxanthin and polyphenols A raw material, a fragrance | flavor, a pH adjuster, an excipient | filler, a sour agent, a coloring agent, an emulsifier, a preservative, etc. can be mix | blended.

In the present invention, the food and drink are other than the pharmaceutical composition and are not particularly limited as long as they are ingestible forms such as solutions, suspensions, emulsions, powders, and solid molded products. Specifically, for example, dairy products such as milk drinks, yogurts, lactic acid bacteria drinks, fermented milk, ice creams, creams, cheeses; soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks Jelly drinks, cocoa, smoothie powdered drinks and sports powdered drinks, nutrition-enriched powdered drinks, cosmetic powdered foods, powdered soup, steamed bread, concentrated drinks, alcoholic drinks, etc .; bread, pasta , Flour products such as noodles, cake mix, fried flour, bread crumbs; confectionery such as chocolate, gum, candy, cookies, gummi, snacks, Japanese confectionery, jelly, pudding, etc .; processed seasonings, flavor seasonings, Seasoning such as cooking mix; curry, busta sauce, potof, stew, Japanese food retort food; processed oil, butter, margarine, spray Oils and fats such as dough and mayonnaise; Instant foods such as freeze-dried foods; Agricultural processed products such as canned agricultural products, jams and marmalades, pickles, boiled beans, cereals, miscellaneous foods; processed marine products; processed livestock products; Frozen foods such as gratin, sugar beet, and fries; liquid foods, animal feeds, tablets, and cosmetics used in the oral cavity.

According to one preferred embodiment of the present invention, the food and drink are milk drinks (which may include processed milk), fermented milk, soft drinks, jelly drinks, tablets, cosmetic powdered foods, powdered drinks, liquid foods, liquids. According to a more preferred embodiment, the food and drink is a milk beverage, fermented milk, soft drink, jelly beverage, prepared milk powder tablet, cosmetic powdered food, and according to a more preferred embodiment, the food and drink The product is a milk beverage (which may include processed milk), fermented milk.

In addition, functional foods, health nutrition foods, supplements, health foods, foods for specified health use, functional indication foods, nutritional functional foods, foods for the sick, infant formulas, milk powders for pregnant and lactating women Or foods and beverages with a disease risk reduction label are included. According to one preferred embodiment of the present invention, the food or drink is a functional food, a health nutrition food, a supplement, a food for specified health use, a functional display food, or a food with a disease risk reduction display.

Here, the indication of disease risk reduction is the indication of food and drink that may reduce the disease risk, and is based on the standards established by the FAO / WHO Joint Food Standards Committee (Codex Committee). , Or with reference to the standard, it can be a defined or recognized display.

Therefore, the food and drink of the present invention are, for example, foods suitable for consumers who expect improvement or alleviation of skin condition deterioration, foods suitable for improvement of skin condition deterioration, that is, so-called foods for specific health use or functions It can be provided as a sex indication food.

In the food and drink and composition of the present invention, in order to obtain a desired effect associated with the absorption of sphingomyelin, it is desirable to set the content of sphingomyelin in the food and drink and the composition within a predetermined range. The specific content can be changed depending on the type and form of the food or drink or the composition, the purpose of prevention / improvement, etc., and thus it is difficult to define it uniformly, but in the composition of the present invention, the adult ( (Weight: 60 kg) per day, milk-derived sphingomyelin can be adjusted to an effective amount that can be ingested at 0.5 to 1500 mg, preferably 1 to 1000 mg, more preferably 5 to 500 mg.

The content of sphingolipid, for example, sphingomyelin, can be measured by a conventional method, but may be measured, for example, according to the description in Examples 1 and 2 described later. Moreover, for example, it can measure using liquid chromatography and using AQUASIL SP100 (4.6X250mm, Senshu Scientific Co., Ltd.) as a column.

At this time, as the mobile phase, for example, a solution in which 0.5 mM phosphate-citrate buffer (pH: 3.0) and methanol are mixed at a ratio of 5 to 95 may be used. The measurement time can be set to 20 minutes, the flow rate of the mobile phase can be set to 0.6 mL / min, the column temperature can be set to 40 ° C., and the absorbance can be detected at 205 nm. As a standard substance, for example, sphingomyelin (derived from milk, Nagara Science Co., Ltd.) can be used, and it can be quantified by the area ratio.

According to another aspect of the present invention, the content of the active ingredient in foods and drinks and compositions can be defined per packaging form. For example, in the case of foods and drinks, the content of sphingolipids is preferably 5 to 1500 mg. 6 to 1000 mg, more preferably 7 to 500 mg, and in the case of a composition, the content of sphingolipid is 0.5 to 1500 mg, preferably 1 to 1000 mg, more preferably 5 to 500 mg. be able to. In addition, the amount (content) per packaging form is not limited to a single intake, and may include intakes for multiple doses or multiple days (for example, for 30 days). In this case, the content of sphingolipid is 5 to 45000 mg, preferably 6 to 30000 mg, more preferably 7 to 15000 mg. In the case of the composition, the content of sphingolipid is 0.5 to 45000 mg, preferably 1 It can be contained in an amount of ˜30000 mg, more preferably 5 to 15000 mg.

The conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, whereas the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per gram of lipid. , Preferably 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg. The conventional general milk drink and fermented milk contain 6 mg of sphingomyelin per gram of lipid, but the food or drink or composition of the present invention contains 7 to 1500 mg of sphingomyelin per gram of lipid. Contained, preferably 8 to 1250 mg, more preferably 9 to 1000 mg, and still more preferably 10 to 750 mg. That is, in one preferred embodiment of the present invention, those having an intentionally increased sphingomyelin content are used.

In the milk beverage and fermented milk of the present invention, when lipid is contained in a normal amount (for example, 3% by weight of lipid), phospholipid is contained at 1 to 300 mg / g, preferably 1.5 to 250 mg / g. More preferably 2 to 200 mg / g, still more preferably 2.5 to 150 mg / g. In the food or drink or composition of the present invention, when lipid is contained in a normal amount, sphingomyelin is contained at 0.2 to 60 mg / g, preferably 0.25 to 50 mg / g, more preferably 0.3. It can be contained at -40 mg / g, more preferably 0.35-30 mg / g.

On the other hand, the conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, but the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per 1 g of lipid. It is preferably contained in an amount of 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg. In addition, in the food or drink or composition of the present invention, when lipid is contained in a small amount, sphingomyelin is contained at 0.05 to 60 mg / g, preferably 0.1 to 50 mg / g, more preferably 0.15 to It can be contained at 40 mg / g, more preferably 0.2 to 30 mg / g.

The conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, but the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per 1 g of lipid. It is preferably contained in an amount of 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg. In addition, in the milk beverage, fermented milk, soft drink, jelly beverage, tablet, and cosmetic powder food of the present invention, when containing almost no lipid (non-fat), sphingomyelin is contained at 0.02 to 60 mg / g. Preferably, it can be contained at 0.04 to 50 mg / g, more preferably 0.06 to 40 mg / g, and still more preferably 0.08 to 30 mg / g.

According to another aspect of the present invention, a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria is orally administered or enterally administered to a subject who wants to take the sphingolipid simultaneously with the sphingolipid. A method for promoting the absorption of sphingolipids. Here, preferably, the sphingolipid is sphingomyelin.

According to still another aspect of the present invention, a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria is orally administered or enterally administered to a subject who wants to take sphingolipids simultaneously with sphingolipids. A method for promoting absorption of ceramide is provided.

Note that, preferably, the above method excludes medical use. The subject is preferably a human or a non-human mammal.

The method is preferably used for a subject in whom intake of sphingolipid is desired, wherein a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria are continuously orally ingested for 2 days or more, or enterally administered. Therefore, it is possible to provide a method for promoting absorption of sphingolipids and a method for promoting absorption of ceramides for subjects in whom intake of sphingolipids is desired.

Hereinafter, the present invention will be described in detail with reference to the following examples, but the present invention is not limited thereto.

Example 1: Evaluation test of absorbability of sphingomyelin in simultaneous administration of yogurt and sphingomyelin To rats, only milk-derived sphingomyelin is administered, or powdered yogurt and milk-derived sphingomyelin are administered simultaneously, lymph The amount of sphingomyelin absorbed was evaluated.

[experimental method]
The experiment was conducted according to the method of Sugawara et al. (J. Lipid Res. 2010, 51, 1761-1769). Specifically, it was as follows.

(1-1) Administration of sphingomyelin and collection of lymph fluid Rats (SD strain, male, body weight: about 350 g) were acclimated and bred in 1 week, and then treated with cannula in the thoracic lymph and stomach using a syringe pump. Then, a buffer solution (glucose: 139 mM, sodium chloride: 85 mM) was fed into the stomach overnight (in about 12 hours) (flow rate: 3 mL / min).

Then, corresponding to each test solution (A), (B) and (C) as will be described later, the rats are divided into 3 groups (a, b, c), and these test solutions are administered into the stomach. From 1 hour before, lymph fluid was collected in Spitz tubes treated with EDTA for 3 groups (a, b, c).

Furthermore, each test solution (A), (B), and (C) (each 3 mL) was sent into the stomach in 1 minute using a syringe pump (flow rate: 3 mL / min), and then the syringe pump was used. The buffer solution was fed into the stomach in 6 hours (flow rate: 3 mL / min).

Then, every hour, lymph fluid was collected in Spitz tubes treated with EDTA for three groups (a, b, c).

(1-2) Test Solution Each test solution (A), (B) and (C) was prepared as follows.
(A) Triolein: 200 mg, bovine serum albumin: 50 mg, and sodium taurocholate: 200 mg were mixed.

(B) Triolein: 195 mg, bovine serum albumin: 50 mg, and sodium taurocholate: 200 mg were mixed with milk-derived sphingomyelin (SM, purity 98%, Nagara Science Co., Ltd.): 5 mg ultrasonically emulsified. It was.

(C) Triolein: 192 mg, bovine serum albumin: 50 mg, and sodium taurocholate 200 mg were mixed with milk-derived sphingomyelin (SM, purity 98%, Nagara Science): 4.75 mg was emulsified with ultrasound. I let you. Along with this, 250 mg of powdered yogurt (YG, fat: about 0%, Meiji Bulgaria yogurt fat, obtained from Meiji Co., Ltd.) was prepared.

(1-3) Structure of Evaluation Group Three groups (a, b, c) corresponding to the test solutions (A), (B), and (C) are shown below, and the contents thereof are shown in Table 1. The number of rats in each group was 5.
(A) Control group: Test solution (A): Intragastric administration at 3 mL / rat (SM: 0 mg / rat).
(B) SM group: Test solution (B): Intragastric administration at 3 mL / rat (SM: 5 mg / rat).
(C) SM + YG group: Test solution (C): 3 mL / rat (SM: 4.75 mg / rat) and YG: 250 mg / rat were intragastrically administered.

 

 

(1-4) Evaluation index After administration of the test solution, the amount of sphingomyelin absorbed in the lymph of the rat was evaluated. Specifically, a ceramide molecular species (d16: 1-C16: 0) and a sphingomyelin molecular species (d16: 1-C16: 0) that are not present in rat lymph and are specifically present in milk-derived sphingomyelin. The difference in absorbability was compared using the kinetics of SM) as an index.

(1-5) Analytical Method Extraction of lipids from lymph collected from rats was performed according to the method of Folch et al. (J. Biol. Chem., 1957, 226, 497-509).
Specifically, lymph: 200 μL (when lymph is collected at 2.5 mL / h), physiological saline: 800 μL is added, and a chloroform-methanol mixture (2: 1 (v / v)): 4 mL And shaken (200 rpm, 15 minutes). Next, after centrifugation (2000 rpm, 10 minutes), the lower layer was transferred to another tube and concentrated by centrifugation, and then 500 μL of methanol was added to prepare a sample for ceramide analysis. Furthermore, the sample for analysis of sphingomyelin was prepared by diluting 10 times with methanol.

As standard products, ceramide (d18: 1-C16: 0, obtained from Avanti Polar Lipids) and sphingomyelin (d18: 1-C16: 0 SM, obtained from Avanti Polar Lipids) were used. Using these standard products as equivalents, ceramide (d16: 1-C16: 0), sphingomyelin (d16: 1-C16: 0 SM) using LC / MS / MS (ACQUITY premier XE (Waters)) Was quantified. At this time, ACQUITY UPLC BEH C18 (2 mm × 100 mm, manufactured by Waters) was used for the column, ammonium acetate (5 mM) / methanol (95%) was used for mobile phase A, and ammonium acetate was used for mobile phase B. (5 mM) / methanol was used.

Then, mobile phase A was started from 100%, and after 30 minutes, mobile phase B was gradiented to 100%, then mobile phase B was made 100% and held for 2 minutes, and after another 3 minutes, The mobile phase A was switched to 100%. Here, the measurement time of one sample in LC / MS / MS is set to 35 minutes, the flow rate of the mobile phase is set to 0.4 mL / min, the temperature of the column is set to 40 ° C., and electrospray ionization is used. Detected with. As analytical variables of LC / MS / MS, capillary voltage is 3000V, source temperature is 120 ° C, solvent removal temperature is 400 ° C, solvent removal gas flow rate is 850L / hour, cone gas flow rate is 50L / hour, cone The voltage was set at 40V / hour.

[result]
The results were as shown in FIG. 1 and FIG.

FIG. 1 shows the transition of the amount of ceramide molecular species (d16: 1-C16: 0). Here, 4, 5, and 6 hours after oral administration of each test solution, the ceramide molecular species amount was higher in the SM + YG group than in the SM group.
FIG. 2 shows changes in the amount of sphingomyelin molecular species (d16: 1-C16: 0 SM). Here, 3, 4, 5, and 6 hours after oral administration of each test solution, the amount of sphingomyelin molecular species was higher in the SM + YG group than in the SM group.

From these results, it was found that simultaneous intake of sphingomyelin and yoghurt promotes absorption of ceramide and sphingomyelin.

Example 2: Evaluation test of absorbability of sphingomyelin in simultaneous intake of yogurt and milk-derived sphingomyelin-rich phospholipid concentrate (MPL) Oral administration of MPL alone or oral administration of yogurt and MPL simultaneously to rats Thus, the amount of ceramide in the blood was evaluated.

[experimental method]
(2-1) Oral administration of MPL and blood collection Rats (SD strain, male, body weight: about 300 g) were bred and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into two groups, and each of the test solutions (D) and (E) shown below was orally administered. Before the administration, 90 minutes after the administration, 180 minutes After 270 minutes and 360 minutes, blood was collected from the tail vein. Then, serum was obtained according to a conventional method.

(2-2) Composition of Evaluation Group (d) MPL Group: Test Solution (D): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
(E) MPL + YG group: Test solution (E): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.

(2-3) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23) that are not present in rat serum but are specifically present in milk-derived sphingomyelin. : 0, d16: 1-C24: 0), and the difference in serum concentration was compared.

(2-4) Analytical method Extraction of serum lipids collected from rats was according to the method of Folch et al. (J. Biol. Chem., 1957, 226, 497-509).
Specifically, physiological saline: 200 μL was added to serum: 50 μL, followed by extraction with a chloroform-methanol mixture (2: 1 (v / v)): 1 mL. Next, after centrifugation (2000 rpm, 10 minutes), the lower layer was transferred to another tube and concentrated by centrifugation, and then methanol: 200 μL was added to prepare a sample for ceramide analysis.

As a standard product, ceramide (d18: 1-C16: 0, d18: 1-C22: 0, d18: 1-C23: 0, d18: 1-C24: 0, obtained from Avanti Polar Lipids) was used. Using these standard products as equivalents, LC / MS / MS (ACQUITY premier XE (manufactured by Waters)) was used and ceramide (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0). At this time, ACQUITY UPLC BEH C18 (2 mm × 100 mm, manufactured by Waters) was used for the column, ammonium acetate (5 mM) / methanol (95%) was used for mobile phase A, and ammonium acetate was used for mobile phase B. (5 mM) / methanol was used.

Then, mobile phase A was started from 100%, and after 30 minutes, mobile phase B was gradiented to 100%, then mobile phase B was made 100% and held for 2 minutes, and after another 3 minutes, The mobile phase A was switched to 100%. Here, the measurement time of one sample in LC / MS / MS is set to 35 minutes, the flow rate of the mobile phase is set to 0.4 mL / min, the temperature of the column is set to 40 ° C., and electrospray ionization is used. Detected with. As analytical variables of LC / MS / MS, capillary voltage is 3000V, source temperature is 120 ° C, solvent removal temperature is 400 ° C, solvent removal gas flow rate is 850L / hour, cone gas flow rate is 50L / hour, cone The voltage was set at 40V / hour.

[result]
The results were as shown in FIG. 3 and FIG.

FIG. 3 shows changes in serum ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0). For ceramide molecular species (d16: 1-C16: 0), 90 and 180 minutes after administration of the test solution, and for ceramide molecular species (d16: 1-C22: 0, d16: 1-C23: 0), At 90, 180, and 270 minutes after administration, ceramide molecular species (d16: 1-C24: 0) were significantly more significant in the MPL + YG group than in the MLP group at 90, 180, 270, and 360 minutes after administration of the test solution. It was overpriced.

FIG. 4 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the MPL + YG group in the area under the time curve than in the MPL group.

It was found that the absorption of sphingomyelin was promoted by simultaneously ingesting a milk-derived phospholipid concentrate and yogurt containing a high content of sphingomyelin.

Example 3: Effect of yogurt and sphingolipid on deterioration of skin barrier function under irradiation of ultraviolet rays Hairless mice whose skin barrier function was deteriorated by irradiation with ultraviolet rays were treated with sphingomyelin or sphingomyelin and yogurt. It was orally ingested for 3 days, and the influence on the skin barrier function (the amount of stratum corneum moisture, the amount of transdermal moisture transpiration (TEWL)) was evaluated.
As the sphingolipid, milk-derived sphingomyelin (SM, purity 98%, Nagara Science) was used.

[experimental method]
(3-1) Induction of deterioration of skin barrier function by ultraviolet irradiation Hairless mice (Hos: HR-1, female, 4 weeks old Hoshino Test Animal Breeding) were acclimatized for 1 week, and then 20 mJ / cm ² Under the conditions, ultraviolet rays (UV-B (GL20SE, Sankyo Electric Co., Ltd.)) were irradiated.

(3-2) Composition of Evaluation Group Using a test system for deterioration of the skin barrier function, the effect of sphingomyelin or sphingomyelin and yogurt on the skin condition was evaluated. There were 8 test systems in each group. The relationship between the group configuration of the animal experiment (configuration of the evaluation group) and the contents of sphingomyelin and yogurt is shown below.

Control group (control group): group in which normal feed is ingested SM group: group in which sphingomyelin is orally administered at 10 mg / kg / day SM + YG group: sphingomyelin and yoghurt in 10 mg / kg / day, 11.3 g / kg / A group to be orally administered on day (however, in the SM group and SM + YG group, collagen is further orally administered at a rate of 1000 mg / kg / day in addition to sphingomyelin and yogurt).

(3-3) Evaluation Test Method For each test group, the stratum corneum water content and TEWL were measured, and the barrier function of the skin was evaluated from these.

(3-3-1) Water content of the stratum corneum The water content of the stratum corneum was measured 5 times / animal using a Corneometer (Corneometer, Curage and Khazaka Electronic GmbH). Among these, the average of three measurement values excluding the maximum value and the minimum value was adopted to obtain the stratum corneum moisture content.

(3-3-2) Transdermal moisture transpiration (TEWL)
Transcutaneous moisture transpiration (TEWL) was measured with a tevameter (Tewemeter MPA580, Curage and Khazaka Electronic GmbH) using a probe kept at 29 ° C. for 20 seconds. About the obtained measurement result, the average of 3 times was employ | adopted and it was set as the amount of transdermal moisture transpiration.

[Evaluation results]
(Corn layer moisture content)
The result was as shown in FIG.
In FIG. 5, the stratum corneum moisture content of the SM group and the SM + YG group was higher than the stratum corneum moisture content of the Control group. Furthermore, the SM + YG group was higher than the SM group. From this, it was considered that the SM + YG group suppressed (improved) the deterioration of the skin barrier function more than the SM group.

(Transdermal moisture transpiration (TEWL))
The result was as shown in FIG.
In FIG. 6, the TE group's TEWL was lower than the control group's TEWL. Further, the SM + YG group was lower than the SM group. From these, it was considered that in the SM + YG group, the deterioration of the skin barrier function was further suppressed (improved) compared to the SM group.

It was suggested that oral intake of sphingolipid and yogurt (fermented milk) further suppresses (improves) the deterioration of the skin barrier function based on ultraviolet rays. Furthermore, it was suggested that the deterioration of the barrier function of the skin is more likely to be suppressed (improved) as the sphingomyelin and yoghurt (fermented milk) are continuously ingested over 3 days.

Example 4: Evaluation test of absorption of sphingomyelin in simultaneous intake of unfermented milk and MPL When rats were orally administered with MPL alone, when yogurt and MPL were orally administered simultaneously, and with unfermented milk and MPL The amount of ceramide in the blood was evaluated for each case of simultaneous oral administration.

[experimental method]
(4-1)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into three groups, and the test solutions (F), (G) and (H) shown below were orally administered. Next, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.

(4-2) Composition of evaluation group (f) MPL group: Test solution (F): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
(G) MPL + YG group: Test solution (G): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.
(H) MPL + unfermented milk group: Test solution (H): skim milk powder (Meiji skim milk powder, obtained from Meiji Co., Ltd.): 1.3 g and MPL: 537 mg (100 mg as the total amount of sphingomyelin) per kg of body weight The dose of was administered.

(4-3) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 7 shows the area under the time curve of the amount of ceramide molecular species in serum. As for any ceramide molecular species, the area under the time curve was significantly higher in the order of the MPL group, the MPL + unfermented milk group, and the MPL + YG group in comparison with the MPL group.

Absorption of sphingomyelin is promoted by simultaneous ingestion of milk-derived phospholipid concentrate and non-fermented milk at a high content of sphingomyelin, but milk-derived phospholipid concentrate at a high content of sphingomyelin It was found that the simultaneous intake of yogurt and yogurt further promotes the absorption of sphingomyelin.

Example 5: Evaluation test of absorption of sphingomyelin in simultaneous intake of yogurt fraction and MPL When rats were orally administered with MPL alone, yogurt and MPL were orally administered simultaneously, yogurt fraction supernatant and The amount of ceramide in blood was evaluated when MPL was orally administered at the same time and when yogurt fraction precipitate and MPL were orally administered at the same time.

[experimental method]
(5-1) Preparation Method of Yogurt Fraction Yogurt (Meiji Bulgaria Yogurt Fat Zero, obtained from Meiji Co., Ltd.) was centrifuged at 6000 rpm for 10 minutes to obtain a yogurt fraction supernatant and a yogurt fraction precipitate. .

(5-2)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into 3 groups, and test solutions (I), (J), (K) and (L) shown below were orally administered. Next, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.

(5-3) Composition of Evaluation Group (i) MPL Group: Test Solution (I): MPL: 540 mg (100 mg as sphingomyelin) was administered per 1 kg of body weight.
(J) MPL + YG group: Test solution (J): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.
(K) MPL + YG supernatant group: Test solution (J): Yogurt supernatant: 743 mg and MPL: 539 mg (100 mg as the total amount of sphingomyelin) were administered per kg of body weight.
(L) MPL + YG precipitation group: Test solution (K): Yogurt precipitation: 455 mg and MPL: 536 mg (100 mg as the total amount of sphingomyelin) were administered per 1 kg of body weight.

(5-4) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 8 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species had significantly higher areas under the time curve in the MPL + YG group and MPL + YG supernatant group than in the MPL group, but there was a significant difference between the MPL group and the MPL + YG precipitation group. There wasn't.

It was found that absorption of sphingomyelin was promoted by orally ingesting a milk-derived phospholipid concentrate containing a high content of sphingomyelin and a supernatant fraction of yogurt at the same time. These results were considered to indicate that the yogurt supernatant fraction contains a component that promotes the absorption of sphingomyelin.

Example 6: Evaluation test of absorption of sphingomyelin in simultaneous intake of lactic acid and MPL When MPL alone was orally administered to rats, yogurt and MPL were orally administered simultaneously, and lactic acid and MPL were orally administered simultaneously For each of these, the amount of ceramide in the blood was evaluated.

[experimental method]
(6-1)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into 3 groups, and the test solutions (L), (M) and (N) shown below were orally administered. Next, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.

(6-2) Composition of Evaluation Group (l) MPL Group: Test solution (L): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
(M) MPL + YG group: Test solution (M): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.
(N) MPL + lactic acid group: Test solution (N): Lactic acid (obtained from Wako Pure Chemical Industries, Ltd.) per kg of body weight: 109 mg (the amount of lactic acid in yogurt was equal to the pH), and MPL: 540 mg (sphingo A dose of 100 mg) was administered as myelin.

(6-3) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 9 shows the area under the time curve of the amount of ceramide molecular species in serum. For all ceramide molecular species, the area under the time curve was significantly higher in the MPL + YG group than in the MPL group, but no significant difference was observed between the MPL group and the MPL + lactic acid group.

These results were considered to indicate that lactic acid in yogurt is not a component that promotes the absorption of sphingomyelin.

Example 7: Evaluation test of absorption of sphingomyelin in simultaneous intake of whey protein and MPL When rats were orally administered MPL alone, yogurt and MPL were orally administered simultaneously, and whey protein and MPL were orally administered simultaneously In each case, the amount of ceramide in the blood was evaluated.

[experimental method]
(7-1)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into 3 groups, and test solutions (O), (P) and (Q) shown below were orally administered. Next, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.

(7-2) Composition of Evaluation Group (o) MPL Group: Test Solution (O): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
(P) MPL + YG group: Test solution (P): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.
(Q) MPL + whey protein group: Test solution (Q): Whey protein (Aracene 8899, obtained from Fontera) per kg of body weight: 109 mg (equal to the weight of whey protein in yogurt), and MPL: 540 mg (sphingo A dose of 100 mg) was administered as myelin.

(7-3) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 10 shows the area under the time curve of the amount of ceramide molecular species in serum. For all ceramide molecular species, the area under the time curve was significantly higher in the MPL + YG group than in the MPL group, but there was no significant difference between the MPL group and the MPL + whey protein group.

These results were considered to indicate that the whey protein in yogurt is not a component that promotes the absorption of sphingomyelin.

Example 8 Evaluation Test of Sphingomyelin Absorption by Simultaneous Intake of Polysaccharide and MPL When rats are orally administered with MPL alone, yogurt and MPL are orally administered simultaneously, and polysaccharide and MPL are orally administered simultaneously In each case, the amount of ceramide in the blood was evaluated.

[experimental method]
(8-1) Purification of polysaccharides Purification of polysaccharides was according to the method of Cerning et al. (J. Dairy Sci., 1992, 75, 692-699). The yogurt supernatant fraction was treated with pronase (Roche) to hydrolyze the protein. Three times the amount of ethanol was added, frozen overnight, and a precipitate containing polysaccharides was obtained by centrifugation. Protein precipitate was removed from the precipitate with an ultrafiltration membrane (Merck Millipore, Centriprep Ultracel YM-3), and the polysaccharide was purified.

(8-2)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into 3 groups, and the test solutions (R), (S) and (T) shown below were orally administered. Subsequently, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a conventional method.

(8-3) Composition of evaluation group (r) MPL group: Test solution (R): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
(S) MPL + YG group: Test solution (S): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as the total amount of sphingomyelin) per kg of body weight Was administered.
(T) MPL + polysaccharide group: Test solution (T): administration of polysaccharide: 52.5 mg (equal to polysaccharide in yogurt) and MPL: 540 mg (100 mg as sphingomyelin) per kg body weight did.

(8-4) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 11 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the area under the time curve in the MPL + YG group and the MPL + polysaccharide group than in the MPL group.

A component that promotes absorption of sphingomyelin by simultaneously ingesting a phospholipid concentrate derived from milk containing a high content of sphingomyelin and a polysaccharide in yogurt, and the polysaccharide in yogurt promotes the absorption of sphingomyelin It was thought that it was one of.

Example 9: Evaluation test of absorption of sphingomyelin in simultaneous intake of yogurt and MPL prepared by lactic acid bacteria and / or bifidobacteria When MPL alone was orally administered to rats, it was prepared by lactic acid bacteria and / or bifidobacteria The amount of ceramide in blood was evaluated for each of the cases where yogurt and MPL were orally administered simultaneously.

(9-1)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, the rats were divided into 3 groups, and the test solutions (U), (V), (W), (X) and (Y) shown below were orally administered. Subsequently, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a conventional method.

(9-2) Composition of Evaluation Group (u) MPL Group: Test Solution (U): MPL: 540 mg (100 mg as sphingomyelin) was administered per 1 kg of body weight.
(V) MPL + YG (1) group: Test solution (V): Yogurt per kg of body weight (1) (prepared by lactic acid bacteria Lactobacillus Gasseri and Streptococcus thermophilus, Meiji Probio Yogurt LG21 Fat Zero, obtained from Meiji Co., Ltd.): A dose of 3 g and MPL: 535 mg (100 mg as the total amount of sphingomyelin) was administered.
(W) MPL + YG (2) group: Test solution (W): per 1 kg of body weight, yogurt (2) (prepared by lactic acid bacteria Lactobacillus delbrueckii subsp. Bulgaricus and Streptococcus thermophilus, Meiji Probio Yogurt R-1 Fat Zero, Meiji Co., Ltd. Obtained): A dose of 11.3 g and MPL: 535 mg (100 mg total sphingomyelin) was administered.
(X) MPL + YG (3) group: Test solution (W): Yogurt per kg of body weight (3) (prepared by lactic acid bacteria Lactobacillus Gasseri, bifidobacteria Bifidobacterium longum, from Nature Megumi fat 0 (zero), Snow Brand Megmilk Co., Ltd. Obtained): A dose of 11.3 g and MPL: 535 mg (100 mg total sphingomyelin) was administered.
(Y) MPL + YG (4) group: Test solution (Y): Yogurt per kg of body weight (4) (prepared by Bifidobacterium longum, bihidas BB536 plain yogurt fat zero, obtained from Morinaga Milk Industry Co., Ltd.): 11.3 g , And MPL: 535 mg (100 mg total sphingomyelin) was administered.

(9-3) Evaluation index After the test solution was orally administered, the amount of ceramide in rat serum was evaluated.
Specifically, ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0) were used as indices.

[result]
The result was as shown in FIG.

FIG. 12 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species had significantly higher areas in the MPL + YG (1) group, the MPL + YG (2) group, the MPL + YG (3) group, and the MPL + YG (4) group as compared to the MPL group.

Ingestion of milk-containing phospholipid concentrate with high content of sphingomyelin and yogurt prepared by various lactic acid bacteria and / or bifidobacteria simultaneously indicates that absorption of sphingomyelin is promoted it was thought.

Example 10: Evaluation test of absorption of glucosylceramide in simultaneous intake of yogurt and glucosylceramide When glucosylceramide (GC) alone was orally administered to a rat, each of cases where yogurt and glucosylceramide L were orally administered simultaneously, The amount of ceramide in the blood was evaluated.

[experimental method]
(10-1)
Rats (SD strain, male, body weight: about 270 g) were acclimated and bred in one week. And after fasting the rats for 16 hours, the rats were divided into 3 groups, and when the test solutions (Y) and (Z) shown below were orally administered, before administration, 90 minutes after administration, 180 minutes later, Blood was collected from the tail vein at each timing after 270 minutes and 360 minutes, and serum was obtained according to a conventional method.

(10-2) Configuration of Evaluation Group (y) GC Group: Test Solution (Y): A dose of GC: 1613 mg (100 mg as glucosylceramide, obtained from Nipunceramide RPS, Nippon Flour) was administered per kg of body weight.
(Z) GC + YG group: Test solution (Z): A dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and GC: 1613 mg per kg of body weight was administered.

(10-3) Evaluation index After carrying the test solution, the amount of ceramide in the rat serum was evaluated.
Specifically, a serum ceramide molecular species (d18: 2-C16: 0) known to increase after glucosylceramide administration according to a report by Sugawara et al. (J. Lipid Res., 2010, 51, 1761-1769). , D18: 2-C23: 0) was used as an index.

[result]
The result was as shown in FIG.

FIG. 13 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the GC + YG group in terms of the area under the time curve than in the GC group.

It was found that the simultaneous absorption of glucosylceramide and yogurt promotes absorption of glucosylceramide.

Claims (19)

A sphingolipid absorption promoter comprising a fermented product and / or cultured product of lactic acid bacteria and / or bifidobacteria. The sphingolipid absorption enhancer according to claim 1, wherein the sphingolipid is sphingomyelin and promotes absorption of the sphingomyelin into a living body. The sphingolipid absorption enhancer according to claim 2, which promotes absorption of milk-derived sphingomyelin into the living body. The sphingolipid absorption promoter according to any one of claims 1 to 3, wherein the sphingolipid is one or more of ceramide, glucosylceramide, and galactosylceramide. The sphingolipid according to any one of claims 1 to 4, wherein the fermentation product and / or culture of lactic acid bacteria and / or bifidobacteria is a milk fermentation product and / or milk culture of lactic acid bacteria and / or bifidobacteria. Absorption enhancer. Sphingolipid absorption promoter containing polysaccharide as an active ingredient. A composition for oral ingestion or enteral administration, comprising the sphingolipid absorption promoter according to any one of claims 1 to 6 and a sphingolipid. A composition for oral ingestion or enteral administration, comprising a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria and additional sphingolipid. The blending ratio of lactic acid bacteria and / or bifidobacteria fermented product and / or culture to sphingolipid is 1 mg of the sphingolipid, and the fermented product and / or cultured product of lactic acid bacterium and / or bifidobacteria (dry weight ( The composition for oral ingestion or enteral administration according to claim 7 or 8, comprising 1) to 10,000 mg of the powder)). The ratio of lactic acid bacteria and / or bifidobacteria fermented and / or cultured product to sphingolipid is 1 mg of sphingolipid, and the fermented and / or cultured product (wet weight) of lactic acid bacteria and / or bifidobacteria The composition for oral ingestion or enteral administration according to claim 7 or 8, comprising 0.01 to 100 g. The composition for oral intake or enteral administration according to any one of claims 7 to 10, wherein the sphingolipid is sphingomyelin. The composition for oral ingestion or enteral administration according to any one of claims 7 to 11, which is used for in vivo action induced by absorption of sphingomyelin into the living body. In vivo action induced is prevention or improvement of skin condition deterioration, cancer suppression action, skin beautification action, infant brain development promotion action, mitochondrial function improvement action, motor function improvement action, visceral fat accumulation suppression and blood adiponectin The composition for oral ingestion or enteral administration according to claim 12, which is selected from the group consisting of a concentration increase promoting action and an infectious disease preventing action. The composition for oral intake or enteral administration according to any one of claims 7 to 11, which is used for prevention, suppression or improvement of deterioration of skin condition. The composition according to claim 14, wherein the deterioration of the skin condition is a deterioration of the barrier function of the skin. A food or drink comprising the sphingolipid absorption promoter according to any one of claims 1 to 6 or the composition according to any one of claims 7 to 15. The food or drink according to claim 16, which is a functional food, a health nutrition food, a supplement, a food for specified health use, a functional indication food or a food with a disease risk reduction indication. A method for promoting absorption of sphingolipids, comprising orally ingesting or enterally administering a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria simultaneously with sphingolipids to a subject who wants to take sphingolipids. . The absorption promotion method according to claim 18, wherein the sphingolipid is sphingomyelin.

Images